News Home

Is Crispr Therapeutics AG (CRSP) a Stock to Watch After Losing -9.76% This Week?

Tuesday, March 30, 2021 03:23 PM | InvestorsObserver Analysts
Is Crispr Therapeutics AG (CRSP) a Stock to Watch After Losing -9.76% This Week?

The market has been down on Crispr Therapeutics AG (CRSP) stock recently. CRSP gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bearish
Crispr Therapeutics AG has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock is higher by 3.1% while the S&P 500 is lower by -0.17% as of 3:04 PM on Tuesday, Mar 30. CRSP has gained $3.43 from the previous closing price of $110.72 on volume of 951,502 shares. Over the past year the S&P 500 has gained 50.93% while CRSP has gained 157.73%. CRSP lost -$5.29 per share in the over the last 12 months.

To see the top 5 stocks in the Biotechnology industry click here.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App